BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nula-cel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nula-cel\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04819841-10290@assetmemo.bio
DTSTAMP:20261121T004016Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nula-cel: Phase 1/2 readout est. (NCT04819841)
DESCRIPTION:Nula-cel\, phase 1/2\, Sickle Cell Disease.\nStudy: Gene Correc
 tion in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Se
 vere Sickle Cell Disease\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nula-cel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04819841
URL:https://assetmemo.bio/drug/nula-cel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
